NSW is about to embark on the largest and most definitive clinical trial ever of medicinal cannabis for chemotherapy-induced nausea and vomiting.
Articles on Clinical trials
Displaying 161 - 180 of 224 articles
Trials into the effectiveness of drugs and treatments struggle to recruit enough participants, yet we rely on their results anyway.
Pay-for-performance for doctors works brilliantly … but only in theory.
Why didn’t you hear about a recent big study on a new heart medication? Because the drug didn’t work. But that doesn’t mean the study wasn’t a success – it was.
A new animal study has shown injections of antibodies might protect against HIV infection, albeit for only a limited time.
If the vaginal ring becomes available for commercial use it will become one of the tools in the HIV prevention toolbox for women alongside female condoms and daily pre-exposure prophylaxis.
The dramatic improvements in survival for children with cancer depend on clinical trials, and these trials depend on parents understanding the possible risks and benefits involved.
Human guinea pigs? On the occasion of Rennes drama, an explanation of what the drug trials in France and how they are controlled.
Meta-analyses that combine many different studies are the gold standard for medical evidence. But they are only as good research they examine.
Tighter regulations of medicines and devices have prevented countless deaths and disabilities. But regulation can’t always protect us from harm.
Women who were found to have lied in a clinical trial testing anti-HIV drugs were heavily criticised. But there are several factors that drove them to lie.
Scientists are developing various products that can provide contraception and protection from sexually transmitted infections and HIV at the same time.
A collaboration between research and industry has produced a promising new drug that could transform many childrens’ lives. It’s also a case study in innovation done right.
Two major clinical trials will be conducted in South Africa in 2016 to test ways of preventing new HIV infections.
Africa’s pharmaceutical industry has mushroomed in the last ten years. But its ability to keep pace with demand is being held back by a number of factors, including a shortage of specialists.
Research should not only benefit the researchers. People who participate in research should also be compensated for the contributions.
When it comes to stem cells, the ways that informed consent has been obtained in the past are not sufficient and improvements are needed.
Was the Ebola vaccine 100% effective, or 100% lucky? The good money is on a percentage somewhere in between, but in truth, we will never know.
We are engaged in one of the great struggles of human knowledge – to liberate clinical trial data.
On Human Experiments – As demand grows for newer and better drugs for an expanding range of conditions, so too does the need for clinical testing.
Top contributors
-
Professor and Director of the Stoneygate Centre for Excellence in Empathic Healthcare, University of Leicester
-
Professor of Pharmaceutical Chemistry, Macquarie University
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Epidemiologist, Cochrane
-
Head of School and Dean of Pharmacy, University of Sydney
-
Professor of medicine, epidemiology & biostatistics, and philosophy, Western University
-
Professor of Immunology, RMIT University
-
Professor of Biostatistics and Epidemiology, Adelaide University
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Senior Lecturer Biostatistics and Data Management, The University of Queensland
-
Membre du comité d'éthique de l'Inserm, Inserm
-
Biostatistician, The University of Melbourne
-
Professor of Bioethics & Medicine, Sydney Health Ethics, Haematologist/BMT Physician, Royal North Shore Hospital and Director, Praxis Australia, University of Sydney
-
Professor of Law, Villanova University
-
Professor, UNSW